Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Data science is revolutionizing the commercial sector. Every business now relies on data to make clever and informed ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

moving inaxaplin into a phase 2/3 AMKD trial at the start of April and inking a $4.9 billion deal to buy Alpine Immune Sciences days later. Buying Alpine gave Vertex control of povetacicept ...

Gemini 2.5 Pro is a multimodal, reasoning model that outperforms competitors from OpenAI, Anthropic, and DeepSeek on key ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...